On February 20, 2024 Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, reported the announcement by Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors (Press release, Immunome, FEB 20, 2024, View Source [SID1234640309]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Earlier this month, Immunome announced that it entered into a definitive asset purchase agreement with Ayala to acquire AL102 and related drug candidate AL101. Completion of the transaction remains subject to customary closing conditions.

"We are pleased with the progress of the RINGSIDE trial," said Bob Lechleider, M.D., Chief Medical Officer of Immunome. "The robust enrollment of the Phase 3 portion affirms our excitement for the potential of AL102. We are also encouraged by the rapidity and depth of the tumor responses observed in Phase 2. We look forward to closing the purchase of AL102 later this quarter or early in the second quarter."